X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in the upcoming H.C. Wainwright 2nd Annual BioConnect Investor Conference, taking place on May 20th, 2024, at the Nasdaq Stock Exchange in New York City.
波士顿,2024 年 5 月 13 日(环球新闻专线)-- X4 制药 (纳斯达克股票代码:XFOR)是一家致力于改善罕见免疫系统疾病患者生活的公司,今天宣布,管理层将参与即将到来的H.C. Wainwright 2和 年度 BioConnect 投资者大会,将于 5 月 20 日举行第四,2024年,在纽约市纳斯达克证券交易所上市。
H.C. Wainwright 2nd Annual BioConnect Investor Conference
Date: Monday, May 20, 2024
Time: 2:00 PM ET
Format: Fireside Chat
Webcast Link
H.C. Wainwright 2和 年度BioConnect投资者大会
日期: 2024 年 5 月 20 日,星期一
时间: 美国东部时间下午 2:00
格式: 炉边聊天
网络直播链接
About X4 Pharmaceuticals
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging our expertise in CXCR4 and immune system biology, we have successfully developed mavorixafor, which has received U.S. approval as XOLREMDI (mavorixafor) capsules in its first indication. We are also evaluating the use of mavorixafor in additional potential indications. X4 corporate headquarters are in Boston, Massachusetts and our research center of excellence is in Vienna, Austria. For more information, please visit our website at www.x4pharma.com.
关于 X4 制药
X4通过为患有罕见免疫系统疾病和重大未满足需求的患者开发和商业化创新疗法,为患者带来进步。利用我们在CXCR4 和免疫系统生物学方面的专业知识,我们成功开发了马沃里沙福尔,其首个适应症作为XOLREMDI(马伏里沙福)胶囊已获得美国批准。我们还在评估马沃里沙福在其他潜在适应症中的使用。X4 公司总部位于马萨诸塞州波士顿,我们的卓越研究中心位于奥地利维也纳。欲了解更多信息,请访问我们的网站 www.x4pharma.com。
Company Contact:
José Juves
Head of Corporate & Patient Affairs
jose.juves@x4pharma.com
公司联系人:
何塞·尤文斯
企业和患者事务主管
jose.juves@x4pharma.com
Investor Contact:
Daniel Ferry
Managing Director, LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
投资者联系人:
丹尼尔·费里
LifeSci Advisors董事总经理
daniel@lifesciadvisors.com
(617) 430-7576
Source: X4 Pharmaceuticals
来源:X4 Pharmicals